[go: up one dir, main page]

MA46334A - Composition pharmaceutique liquide - Google Patents

Composition pharmaceutique liquide

Info

Publication number
MA46334A
MA46334A MA046334A MA46334A MA46334A MA 46334 A MA46334 A MA 46334A MA 046334 A MA046334 A MA 046334A MA 46334 A MA46334 A MA 46334A MA 46334 A MA46334 A MA 46334A
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
liquid
composition
pharmaceutical
Prior art date
Application number
MA046334A
Other languages
English (en)
Inventor
Rio Alessandra Del
Carmela Sabina
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Publication of MA46334A publication Critical patent/MA46334A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA046334A 2016-09-27 2017-09-26 Composition pharmaceutique liquide MA46334A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16190957 2016-09-27

Publications (1)

Publication Number Publication Date
MA46334A true MA46334A (fr) 2019-08-07

Family

ID=57047015

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046334A MA46334A (fr) 2016-09-27 2017-09-26 Composition pharmaceutique liquide

Country Status (12)

Country Link
US (3) US10961314B2 (fr)
EP (1) EP3518891A1 (fr)
JP (3) JP2019534863A (fr)
KR (1) KR102546471B1 (fr)
CN (1) CN109862880A (fr)
AU (1) AU2017333367A1 (fr)
BR (1) BR112019005328A2 (fr)
CA (1) CA3037440A1 (fr)
MA (1) MA46334A (fr)
RU (1) RU2019112680A (fr)
WO (1) WO2018060210A1 (fr)
ZA (1) ZA201901590B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
KR20190120439A (ko) 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
CN109350740B (zh) * 2017-11-30 2023-06-20 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
US11427639B2 (en) * 2018-04-02 2022-08-30 Richter Gedeon Nyrt. Antibody-containing aqueous formulation and use thereof
AU2019372568B2 (en) * 2018-10-31 2025-01-30 Richter Gedeon Nyrt Aqueous pharmaceutical formulations
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
EP3714902B1 (fr) * 2020-03-13 2024-08-28 LEK Pharmaceuticals d.d. Stabilisation de compositions pharmaceutiques comprenant un polysorbate
CN113456582B (zh) * 2020-03-30 2024-06-14 鲁南制药集团股份有限公司 重组人源化抗pd-1单克隆抗体的液体制剂
WO2021228917A1 (fr) * 2020-05-15 2021-11-18 F. Hoffmann-La Roche Ag Prévention de la formation de particules visibles dans des solutions de protéines parentérales
WO2021242776A2 (fr) * 2020-05-26 2021-12-02 Truebinding, Inc. Méthodes de traitement de maladies inflammatoires par blocage de la galectine-3
US11365248B2 (en) * 2020-06-29 2022-06-21 Anovent Pharmaceutical (U.S.), Llc Formulation of tocilizumab and method for treating COVID-19 by inhalation
WO2022037606A1 (fr) * 2020-08-19 2022-02-24 Bio-Thera Solutions, Ltd. Formulations liquides comprenant des anticorps humanisés à concentrations élevées pour le traitement de maladies liées à il-6
KR20220028972A (ko) * 2020-08-31 2022-03-08 (주)셀트리온 안정한 약제학적 제제
WO2022139457A1 (fr) * 2020-12-24 2022-06-30 이니스트에스티 주식회사 Composition d'injection de venin d'abeille comprenant 50 à 99 % de bvpla2 issu d'un extrait de venin d'abeille, et son procédé de préparation
WO2024245170A1 (fr) * 2023-05-26 2024-12-05 Bio-Thera Solutions, Ltd. Formulations liquides comprenant des anticorps humanisés à concentrations élevées pour le traitement de maladies liées à l'il-6

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0628639T3 (da) 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
SI1475101T1 (sl) 2002-02-14 2011-03-31 Chugai Pharmaceutical Co Ltd Farmacevtski proizvodi iz raztopine, ki vsebuje protitelo
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN102301235B (zh) * 2008-11-28 2014-11-19 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
EP2196476A1 (fr) * 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
RU2565809C2 (ru) * 2009-03-19 2015-10-20 Чугаи Сейяку Кабусики Кайся Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
WO2011061712A1 (fr) * 2009-11-20 2011-05-26 Biocon Limited Formulations d'anticorps
JP2013515754A (ja) * 2009-12-29 2013-05-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規な抗体製剤
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
KR20190120439A (ko) * 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
JP2015536934A (ja) * 2012-10-25 2015-12-24 メディミューン,エルエルシー 安定した低粘度の抗体製剤
CN109350740B (zh) * 2017-11-30 2023-06-20 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
WO2022037606A1 (fr) * 2020-08-19 2022-02-24 Bio-Thera Solutions, Ltd. Formulations liquides comprenant des anticorps humanisés à concentrations élevées pour le traitement de maladies liées à il-6
CN117858722A (zh) * 2021-08-18 2024-04-09 百奥泰生物制药股份有限公司 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂

Also Published As

Publication number Publication date
KR102546471B1 (ko) 2023-06-21
ZA201901590B (en) 2020-10-28
US20190218300A1 (en) 2019-07-18
CA3037440A1 (fr) 2018-04-05
US20240150479A1 (en) 2024-05-09
JP2024178197A (ja) 2024-12-24
US20210261673A1 (en) 2021-08-26
WO2018060210A1 (fr) 2018-04-05
BR112019005328A2 (pt) 2019-06-18
JP2019534863A (ja) 2019-12-05
US10961314B2 (en) 2021-03-30
RU2019112680A3 (fr) 2020-12-15
JP2022188075A (ja) 2022-12-20
CN109862880A (zh) 2019-06-07
AU2017333367A1 (en) 2019-04-04
EP3518891A1 (fr) 2019-08-07
RU2019112680A (ru) 2020-10-29
KR20190062440A (ko) 2019-06-05

Similar Documents

Publication Publication Date Title
MA46334A (fr) Composition pharmaceutique liquide
EP3476386C0 (fr) Composition pharmaceutique liquide
HK1243650A1 (zh) 包含美洛昔康的藥物組合物
MA45562A (fr) Préparation pharmaceutique liquide stable
SI3529248T1 (sl) Farmacevtske spojine
DK3532029T3 (da) Flydende farmaceutisk sammensætning
EP3454899C0 (fr) Composition pharmaceutique
DK3558278T3 (da) Flydende cannabinoidsammensætning
MA43705A (fr) Formulation pharmaceutique
EP3452075A4 (fr) Composition pharmaceutique ophtalmique
EP3390626A4 (fr) Formulation liquide d'alpha-amylase
EP3395325A4 (fr) Composition cosmétique liquide
DK3529240T3 (da) Farmaceutiske forbindelser
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
DK3496551T3 (da) Flydende allulosesammensætning
ZA201907313B (en) Stable liquid pharmaceutical composition
DK3145488T3 (da) Flydende farmaceutiske forbindelse
MA47516A (fr) Composition pharmaceutique
DK3181245T3 (da) Dyseenhed for flydende substanser
MA42964A (fr) Préparation pharmaceutique anti-vieillissement
LT3419595T (lt) Stabili skysta gonadotropino kompozicija
EP3207149C0 (fr) Composition pharmaceutique présentant une stabilité améliorée
EP3360547A4 (fr) Composition pharmaceutique bactéricide et virucide
EP3424509A4 (fr) Préparation pharmaceutique liquide
EP3383371A4 (fr) Formulation pharmaceutique